NEPH - Nephros, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5900
-0.0200 (-3.28%)
At close: 2:45PM EDT
Stock chart is not supported by your current browser
Previous Close0.6100
Open0.5900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5900 - 0.5900
52 Week Range0.4100 - 0.7300
Volume500
Avg. Volume22,506
Market Cap37.856M
Beta (3Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0530
Earnings DateJan 2, 2019 - Jan 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.65
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Nephros Announces $2 Million Private Placement

    SOUTH ORANGE, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (NEPH) (the “Company”), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that it has completed a private placement in which it sold approximately 4.4 million shares of common stock at a purchase price of $0.45 per share, resulting in total gross proceeds to the company of $2 million. The private placement was led by the Pessin and Farwell families. “We appreciate the ongoing support of our investors,” said Daron Evans, President and CEO of Nephros.

  • GlobeNewswire13 days ago

    Nephros Reports First Quarter Financial Results

    Revenues up 80% over Q1 2018 Driven by Hospital Footprint Expansion Reiterates 2019 Guidance for Revenue Growth of 50% to 65% SOUTH ORANGE, N.J., May 08, 2019 -- via.

  • GlobeNewswire20 days ago

    Nephros Appoints Tom Gwydir to its Board of Directors

    SOUTH ORANGE, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (NEPH), a commercial stage company that develops and sells high-performance water purification products to the medical device and commercial markets, today announced the appointment of Tom Gwydir to its Board of Directors. “We are very pleased to welcome Tom to the Nephros board,” said Daron Evans, President and CEO of Nephros. “I am very excited to join the Nephros board,” said Tom Gwydir.

  • GlobeNewswire20 days ago

    Nephros to Report First Quarter 2019 Financial Results on May 8, 2019

    SOUTH ORANGE, NJ, May 01, 2019 -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid.

  • GlobeNewswire26 days ago

    Taglich Brothers Initiates Coverage of Nephros, Inc.

    Nephros Inc., headquartered in South Orange, NJ, is a water purification company that develops and sells high performance filters and ultrafilters primarily to hospitals for the prevention of infection from waterborne pathogens and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrates. An acquisition in December 2018 expanded NEPH’s potential customer base to include the food service and hospitality industries.  Specialty Renal Products (a 62.5% owned subsidiary) is a development stage company focused on improving therapies for patients with renal disease. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization.

  • GlobeNewswire27 days ago

    Nephros to Present at Taglich Brothers 16th Annual Investment Conference on April 30, 2019 in New York City

    SOUTH ORANGE, NJ, April 24, 2019 -- via NEWMEDIAWIRE -- Nephros, Inc.(OTCQB: NEPH), a commercial stage company that develops and sells high performance liquid purification.

  • GlobeNewswirelast month

    Nephros Announces Preliminary Financial Results for First Quarter 2019

    SOUTH ORANGE, NJ, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (NEPH), a commercial stage medical device and commercial products company that develops and sells high performance water purification products, today announced preliminary financial results for the quarter ended March 31, 2019. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of endotoxins and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients.

  • GlobeNewswire2 months ago

    Nephros to Present at the Spring Investor Summit on April 1st in New York City

    SOUTH ORANGE, NJ, March 29, 2019 -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification.

  • ACCESSWIRE2 months ago

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • GlobeNewswire2 months ago

    Nephros Reports 2018 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

    Annual Product Revenues Up 54% SOUTH ORANGE, N.J., March 12, 2019 -- Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid.

  • ACCESSWIRE2 months ago

    Nephros to Present at the 2019 LD Micro Virtual Conference

    LOS ANGELES, CA / ACCESSWIRE / March 7, 2019 / Nephros, Inc. (NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will be presenting at the second annual LD Micro Virtual Conference on Tuesday, March 12th at 12:20 PM Eastern Time. Daron Evans, CEO of Nephros will be giving the presentation. "We are delighted to be hosting our second virtual event in order to showcase some of the truly unique names in micro-cap," stated Chris Lahiji, President of LD Micro.

  • GlobeNewswire2 months ago

    Nephros to Report Fourth Quarter and Year End 2018 Financial Results on March 12th, 2019

    SOUTH ORANGE, NJ, March 06, 2019 -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid.

  • GlobeNewswire3 months ago

    Nephros Appoints Alisa Lask to its Board of Directors

    SOUTH ORANGE, NJ, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced the appointment of Alisa Lask to its Board of Directors. Additionally, Moshe Pinto has resigned from the Nephros Board of Directors to focus his activities on the Board of Directors of Specialty Renal Products, Inc., Nephros’ majority-owned subsidiary developing a second generation hemodiafiltration device.  “We are pleased to welcome Alisa to our board,” said Daron Evans, CEO of Nephros.

  • GlobeNewswire4 months ago

    Nephros Announces Preliminary Financial Results for Fiscal Year 2018

    SOUTH ORANGE, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced preliminary financial results for fiscal year 2018. The addition of Biocon into the Nephros family provides additional revenue potential in our core hospital market and exciting growth opportunities in new markets. Nephros ended fiscal year 2018 with approximately $4.5 million in cash on a consolidated basis.

  • GlobeNewswire5 months ago

    Nephros Announces Acquisition of Biocon

    SOUTH ORANGE, NJ, Jan. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (NEPH) (“Nephros”), a commercial stage company that develops and sells high performance liquid purification ultrafilters, today announced that it has acquired Biocon 1, LLC and its affiliate Aether Water Systems, LLC (together, “Biocon”), adding a growing water filtration business that targets the food service, hospitality, and commercial markets. The acquisition was completed on December 31, 2018.

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Nephros, Inc. (NEPH)

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Nephros, Inc. (NEPH) with a Target Price of $1.80. Based in South Orange, NJ, Nephros, Inc. (OTCQB: NEPH "Nephros") is a commercial stage medical device company, with innovative filtration products targeting large market opportunities including hospital infection control and advanced renal care. Nephros was founded by healthcare professionals associated with Columbia University Medical Center / New York Presbyterian Hospital to develop a hemodiafiltration (HDF) device as an alternative to hemodialysis.

  • GlobeNewswire6 months ago

    Nephros to Present at the 11th Annual LD Micro Main Event

    Presentation Scheduled for 9:30 AM PT on Tuesday, December 4th SOUTH ORANGE, NJ, Dec. 03, 2018 -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial.

  • GlobeNewswire6 months ago

    Nephros Reports Third Quarter 2018 Financial Results

    Quarterly Product Revenue Up 96% Year-over-Year; Total Revenue Up 88% SOUTH ORANGE, N.J., Nov. 08, 2018 -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a.

  • GlobeNewswire7 months ago

    Nephros to Report Third Quarter 2018 Financial Results on November 8th, 2018

    SOUTH ORANGE, NJ, Nov. 01, 2018 -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid.